TISIDB

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Note=A truncated form, major form, with the C-terminal part missing, is mostly found in the cytoplasm and a little in the nucleus. The full-length, minor form, is found in the nucleus.
Domain	PF00481 Protein phosphatase 2C
Function	Protein phosphatase that inactivates multifunctional CaM kinases such as CAMK4 and CAMK2 (By similarity). Dephosphorylates and inactivates PAK. May play a role in the inhibition of actin fiber stress breakdown and in morphological changes driven by TNK2/CDC42. Dephosphorylates PRKAA2 (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001933 negative regulation of protein phosphorylation GO:0006469 negative regulation of protein kinase activity GO:0006470 protein dephosphorylation GO:0007015 actin filament organization GO:0016311 dephosphorylation GO:0030038 contractile actin filament bundle assembly GO:0031032 actomyosin structure organization GO:0032231 regulation of actin filament bundle assembly GO:0032233 positive regulation of actin filament bundle assembly GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0033673 negative regulation of kinase activity GO:0035690 cellular response to drug GO:0035970 peptidyl-threonine dephosphorylation GO:0042326 negative regulation of phosphorylation GO:0042493 response to drug GO:0043149 stress fiber assembly GO:0044089 positive regulation of cellular component biogenesis GO:0051017 actin filament bundle assembly GO:0051348 negative regulation of transferase activity GO:0051492 regulation of stress fiber assembly GO:0051493 regulation of cytoskeleton organization GO:0051495 positive regulation of cytoskeleton organization GO:0051496 positive regulation of stress fiber assembly GO:0061572 actin filament bundle organization
Molecular Function	GO:0004721 phosphoprotein phosphatase activity GO:0004722 protein serine/threonine phosphatase activity GO:0016791 phosphatase activity GO:0042578 phosphoric ester hydrolase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PPM1E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PPM1E in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PPM1E in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.02	0.936
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.379	0.406
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.314	0.411
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.059	0.931
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.636	0.691
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.678	0.704
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.759	0.222
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.506	0.585
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.131	0.238
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.085	0.854
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.464	0.489
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.803	0.00179

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PPM1E in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	5.1	-1.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPM1E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPM1E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPM1E. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPM1E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PPM1E expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PPM1E and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PPM1E
Name	protein phosphatase, Mg2+/Mn2+ dependent, 1E
Aliases	POPX1; KIAA1072; PP2CH; CaMKP-N; partner of PIX 1; nuclear calmodulin-dependent protein kinase phosphatase; ......
Chromosomal Location	17q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PPM1E collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PPM1E